Resveratrol — Stack & Timing
Educational timing and stacking information based on how Resveratrol has been studied. Not a prescription. Not medical advice.
This is educational information only. Consult a healthcare provider before starting any supplement.
Stack & Timing Guidance
Educational summary based on how Resveratrol has been studied and commonly used.
Commonly studied timing
Resveratrol is fat-soluble and its bioavailability appears to improve when taken with a meal containing dietary fat; morning dosing with breakfast is a common protocol in human trials. There is limited evidence favoring a specific time of day, but consistency with meals is generally recommended.
Dose ranges used in studies
Human RCTs have studied doses ranging from roughly 75 mg to 1000 mg per day, with metabolic and glycemic studies often using 150–500 mg; doses above 1 g/day have been tested but are less common and may carry higher risk of side effects.
↑ These are ranges from research studies, not personal dosing recommendations. Discuss with a clinician.
Commonly paired with
Both are polyphenols with overlapping antioxidant and anti-inflammatory mechanisms; combining them may offer complementary pathway coverage.
Piperine is thought to inhibit metabolism of resveratrol in the gut and liver, potentially increasing its bioavailability.
Pterostilbene is a methylated analog of resveratrol with reportedly higher bioavailability; some experts favor it over or alongside resveratrol for similar sirtuin/AMPK-related targets.
Resveratrol is proposed to activate sirtuins (SIRT1), which are NAD+-dependent enzymes; pairing with NAD+ precursors is theorized to enhance sirtuin activity.
Safety & interactions
Resveratrol is generally well-tolerated at doses up to ~1 g/day in short-term studies, but gastrointestinal side effects (nausea, diarrhea) can occur at higher doses. Long-term safety data in humans is limited, and high-dose use during pregnancy should be avoided given potential hormonal and developmental effects noted in preclinical research.
- •Anticoagulants (e.g., warfarin, direct oral anticoagulants): resveratrol may inhibit CYP2C9 and affect drug metabolism, potentially altering anticoagulant levels and bleeding risk.
- •Antiplatelet drugs and NSAIDs: additive antiplatelet activity may increase bleeding risk.
- •CYP450 substrates: resveratrol can inhibit multiple CYP enzymes (CYP3A4, CYP2D6), potentially raising plasma levels of co-administered drugs.
- •Estrogen-modulating medications: resveratrol has weak phytoestrogenic activity and may interact with hormone therapies or tamoxifen.
Individuals who are pregnant or breastfeeding should avoid resveratrol supplementation due to insufficient safety data and potential hormonal effects. Those on anticoagulant therapy, hormone-sensitive conditions (e.g., estrogen-receptor-positive cancers), or medications metabolized by CYP450 enzymes should consult a healthcare provider before use.